Press Releases
<< Back
Horizon Technology Finance Provides Third Quarter 2024 Portfolio Update
- HRZN Originates
-
“We made excellent progress in the third quarter with respect to originating new, high-quality investments, as the venture environment continues to show improvement,” said
Third Quarter 2024 Portfolio Update
Originations
During the third quarter of 2024, HRZN funded a total of
-
$25.0 million to a new portfolio company,Hometeam Technologies, Inc. (dbaVesta Healthcare ), a tech-enabled clinical services company that integrates caregivers, patients and the healthcare delivery system to monitor chronic conditions of high-risk patients. -
$16.0 million to an existing portfolio company,Spineology, Inc. , a developer of anatomy-conserving technology solutions for use in lumbar spinal fusion procedures. -
$15.0 million to a new portfolio company,GT Medical Technologies, Inc. , a developer of a proprietary solution to treat brain tumors. -
$15.0 million to a new portfolio company,Infobionic, Inc. , a developer of an FDA-cleared SaaS remote monitoring system to help treat cardiac arrythmia. -
$10.0 million to a new portfolio company,Pivot Bio, Inc. , a developer of natural microbial products that ensure crops receive essential nitrogen needed to grow. -
$10.0 million to a new portfolio company, a developer of a connected digital supply chain for custom manufacturing that networks highly-vetted manufacturing partners around the globe. -
$1.0 million to an existing portfolio company,Swift Health Systems, Inc. (dba InBrace), a developer of teeth straightening technology that provides an alternative to traditional braces and aligners. -
$0.6 million to an existing portfolio company, a developer of a breathalyzer test to detect recent cannabis use. -
$0.5 million to an existing affiliated portfolio company, a builder of conservation memorial forests that offer sustainable alternatives to cemeteries.
Liquidity Events and Partial Paydowns
HRZN experienced liquidity events from four portfolio companies in the third quarter of 2024, consisting of principal prepayments of
-
In July,
MyForest Foods Co. (“MyForest Foods”) prepaid its outstanding principal balance of$3.8 million on its venture loan, plus interest, end-of-term payment and prepayment fee. HRZN continues to hold warrants inMyForest Foods . -
In July,
Lemongrass Holdings, Inc. (“Lemongrass”) prepaid its outstanding principal balance of$6.2 million on its venture loan, plus interest, end-of-term payment and prepayment fee. HRZN continues to hold warrants in Lemongrass. -
In July,
Slingshot Aerospace, Inc. (“Slingshot Aerospace”) prepaid its outstanding principal balance of$20.0 million on its venture loan, plus interest, end-of-term payment and prepayment fee. HRZN continues to hold warrants inSlingshot Aerospace . -
In July, with the proceeds of a new loan from the Horizon Platform, Spineology paid its outstanding principal balance of
$7.5 million on its venture loan, plus interest and end-of-term payment. HRZN continues to hold warrants in Spineology.
HRZN also received prepayments of principal from two portfolio companies in the aggregate amount of
Principal Payments Received
During the third quarter of 2024, HRZN received regularly scheduled principal payments on investments totaling
Commitments
During the quarter ended
Pipeline and Term Sheets
As of
During the quarter, HTFM received signed term sheets that are in the approval process, which may result in the Horizon Platform providing up to an aggregate of
Warrant and Equity Portfolio
As of
About
Forward-Looking Statements
Statements included herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009923474/en/
Investor Relations:
ICR
ir@horizontechfinance.com
(646) 200-8885
Media Relations:
ICR
HorizonPR@icrinc.com
(646) 677-1819
Source: